Clone Number: FP3.2 [FPS392]
Immunogen: KLH-conjugated phosphopeptide RHKKLMFKTEGPDS[P]D, corresponding to amino acids 378-393 of human p53.
Concentration: 1 mg/ml
Format: Purified by protein-A affinity chromatography.
Storage buffer: Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Additional info: The tumour suppressor protein p53 is a key element of intracellular anticancer protection. It mediates cell cycle arrest or apoptosis in response to DNA damage or to starvation for pyrimidine nukleotides. It is up-regulated in response to these stress signals and stimulated to activate transcription of specific genes, resulting in expression of p21waf1 and other proteins involved in G1 or G2/M arrest, or proteins that trigger apoptosis, such as Bcl-2. The structure of p53 comprises N-terminal transactivation domain, central DNA-binding domain, oligomerisation domain, and C-terminal regulatory domain. There are various phosphorylation sites on p53, of which the phosphorylation at Ser15 is important for p53 activation and stabilization.SpecificityThe mouse monoclonal antibody LpMab-23 recognizes an extracellular epitope on human cancer type PDPN, a transmembrane glycoprotein, serving as a prognostic marker of oral carcinoma. This antibody recognizes an altered glycosylation pattern that occurs on oral cancer cells and it shows minimal reactivity with the surrounding non-cancerous tissue.Application detailsImmunohistochemistry (paraffin sections): Standard ABC technique (DAB+), pretreatment: high temperature antigen retrieval (microwave, pressure cooker) in 10 mM citrate buffer pH 6.0 or 1 mM EDTA-NaOH buffer pH 8.0, recommended dilution: 10 μg/ml, incubation: 1 hour at RT; or overnight at 4°C, positive tissue: breast carcinoma with high level of wild-type p53.
Western blotting: recommended dilution: 1 μg/ml.
English
Deutsch
